MAPS is sponsoring a single-site, open-label Phase 2 study designed to test the feasibility of administering MDMA in conjunction with psychotherapy for combat-related treatment-resistant PTSD in U.S. military veterans currently enrolled in services at the Department of Veterans Affairs (VA) in Loma Linda, California. This study is an investigator initiated trial and is currently active and recruiting.